1. Patients receiving secukinumab every 2-weeks showed superior clinical response rates compared to those receiving placebo. 2. Secukinumab was well-tolerated, ...
1. Patients receiving secukinumab every 2-weeks showed superior clinical response rates compared to those receiving placebo. 2. Secukinumab was well-tolerated, ...
1. Significantly more patients in the bimekizumab group reached ACR50 at week 16 compared to the placebo. 2. Fungal infections ...
1. Patients who continued anti-tumor necrosis factor (TNF) after 24 weeks of pregnancy had improved inflammatory bowel disease (IBD) activity ...
1. Olokizumab was superior to placebo in improving rheumatoid arthritis (RA) symptoms. 2. Olokizumab was also noninferior to adalimumab in ...
1. Clinical remission at 52 weeks was similar between ustekinumab and adalimumab. 2. Patient-reported outcomes of stool frequency and abdominal ...
1. Adalimumab was efficacious when used simultaneously with wide-excision surgery for treatment of moderate to severe hidradenitis suppurativa (HS). Evidence ...
1. Janus kinase (JAK) inhibitor upadacitinib showed non-inferior efficacy in improving psoriatic arthritis compared to standard-of-care adalimumab. 2. High-dose upadacitinib ...
